Study of XB010 in Subjects With Solid Tumors
Recruiting
Phase 1
Interventional Study
Locally Advanced or Metastatic Solid Tumors
Esophageal Squamous Cell Cancer
Head and Neck Squamous Cell Cancer
NSCLC (Non-small Cell Lung Cancer)
Hormone-receptor-positive Breast Cancer
Triple Negative Breast Cancer (TNBC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 396 (estimated)
- Sponsor
- Exelixis · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
* Age 18 years or older on the day of consent.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
* Adequate organ and marrow function.
* Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.
* …
Contacts
Backup or International
650-837-7400
CONTACT